Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03460067 · ClinicalTrials.gov registry record · NA
Omission of Radiation in Patients With Her-2 Positive Breast Cancer
A NA study of HER2-positive Breast Cancer, sponsored by University of Kansas Medical Center.
- Active
- Registry status
- NA
- Development phase
- 12
- Enrollment target
- 1
- Study location
NCT03460067: Active NA study of HER2-positive Breast Cancer, sponsored by University of Kansas Medical Center.
NCT03460067 is a NA study of HER2-positive Breast Cancer that is active but no longer recruiting, run by University of Kansas Medical Center. The registered enrollment target is 12 participants, below the 236-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03460067, a NA study of HER2-positive Breast Cancer, is active but no longer recruiting, sponsored by University of Kansas Medical Center.
- ACTIVE NOT RECRUITING
- Registry status
- NA
- Development phase
- 12 participants
- Enrollment target
- 1
- Study location
Study Summary
The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone.
Primary Outcome
Defined as biopsy positive her-2 positive tumor in the same breast
Conditions Studied
Interventions
- RADIATION Omission of Radiation
Study Locations (1)
Kansas
- University of Kansas Medical Center/ Cancer Center - Kansas City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 12 participants |
| Start Date | 2018-02-23 |
| Est. Completion | 2027-07-16 |
| Phase | NA |
What the registry record for NCT03460067 still lists
NCT03460067 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 12 participants, a relatively small participant target, below the 236-participant average among 58 other HER2-positive Breast Cancer trials with a reported enrollment target (95% lower).
The record links to 1 condition, with HER2-positive Breast Cancer appearing as the primary indexed condition, and to 1 intervention - of which Omission of Radiation is the first listed.
NCT03460067 reports a single indexed study location in Kansas.
Frequently Asked Questions
What is clinical trial NCT03460067 about?
NCT03460067 is a clinical study titled "Omission of Radiation in Patients With Her-2 Positive Breast Cancer". The primary objective of this study is to describe the rate of local control in patients with her-2 positive early stage breast cancer with a complete response to chemotherapy and lumpectomy alone.
What is the current status of trial NCT03460067?
This trial is currently active not recruiting. It is a NA study. The enrollment target is 12 participants. The study started on 2018-02-23. Estimated completion is 2027-07-16.
What conditions does trial NCT03460067 study?
This clinical trial studies the following conditions: HER2-positive Breast Cancer.
What interventions are being tested in trial NCT03460067?
The interventions under investigation include: Omission of Radiation (RADIATION).
Who is sponsoring clinical trial NCT03460067?
This trial is sponsored by University of Kansas Medical Center, which has 408 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03460067 being conducted?
This trial has 1 study location across Kansas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for HER2-positive Breast Cancer
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03460067's enrollment target sits among peer trials
12 57th of 58 higher than 2 of 58 other HER2-positive Breast Cancer trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other HER2-positive Breast Cancer trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
NearWave Optical Molecular Monitoring
RECRUITING · NA
-
Prolonged Overnight Fasting and/or Exercise on Fatigue and Other Patient Reported Outcomes in Women With Hormone Receptor Positive Advanced Breast Cancer
RECRUITING · NA
-
Screening Magnetic Resonance Imaging of the Brain in Patients With Breast Cancer
RECRUITING · NA
-
Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer
ACTIVE NOT RECRUITING · NA
-
The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast Cancer
RECRUITING · Phase 2
-
TRUDI: TDXD+Durva in HER2+/Low IBC
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02602769 · 12 participants
Whole Transcriptome Profiling and Metabolic Phenotyping in Children With ROHHAD Syndrome
- NCT02605421 · 12 participants · Phase 2
Myeloablative Consolidation Therapy and Tandem Autologous Stem Cell Rescue in Patients With High-Risk Neuroblastoma
- NCT02619448 · 12 participants · Early Phase 1
Concurrent Chemotherapy Plus HFR Radiation Therapy in Inoperable NSCLC
- NCT03311503 · 12 participants · Phase 1
Phase I/II Trial of Lentiviral Gene Transfer for SCID-X1 With Low Dose Targeted Busulfan Conditioning
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI